We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
With just six months to go before the end of the transition period in the UK’s exit from the European Union, European drug industry groups said they are “extremely concerned” about the lack of progress in trade talks and they are urging negotiators to agree to drug supply chain protections outside of the talks. Read More
Ridgeback Biotherapeutics in July will launch two phase 2 trials of its investigational antiviral EIDD-2801 as a potential COVID-19 treatment. Read More
In a victory for Mylan, a West Virginia federal court has invalidated a key patent on Biogen’s blockbuster multiple sclerosis drug Tecfidera (dimethyl fumarate). Read More
A European Union-backed research consortium has identified raloxifene, an osteoporosis drug, as a possible treatment for mildly symptomatic COVID-19 patients. Read More
Chinese drugmaker Clover Biopharmaceuticals has dosed the first participants in a phase 1 trial of its COVID-19 vaccine candidate, an Australian study that’s also evaluating two adjuvants contributed by its research partners. Read More
The UK government’s decision to ban the export of dexamethasone, the inexpensive anti-inflammatory drug that’s shown promise as a COVID-19 treatment, is getting pushback from within the country. Read More